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Abstract   27 
Background 28 
Adjunctive dexamethasone reduces mortality from tuberculous meningitis (TBM) but not disability, 29 
which is associated with brain infarction. We hypothesised that aspirin prevents TBM-related brain 30 
infarction through its anti-thrombotic, anti-inflammatory, and pro-resolution properties. 31 
Methods 32 
We conducted a randomised controlled trial in HIV-uninfected adults with TBM of daily aspirin 81mg 33 
or 1000mg, or placebo, added to the first 60 days of anti-tuberculosis drugs and dexamethasone 34 
(NCT02237365). The primary safety endpoint was gastro-intestinal or cerebral bleeding by 60 days; 35 
the primary efficacy endpoint was new brain infarction confirmed by magnetic resonance imaging or 36 
death by 60 days. Secondary endpoints included 8-month survival and neuro-disability; the number 37 
of grade 3&4 and serious adverse events; and cerebrospinal fluid (CSF) inflammatory lipid mediator 38 
profiles. 39 
Findings 40 
41 participants were randomised to placebo, 39 to aspirin 81mg/day, and 40 to aspirin 1000mg/day 41 
between October 2014 and May 2016. TBM was proven microbiologically in 92/120(76.7%) and 42 
aseli e rai  i agi g re ealed ≥  i far t i  / . %  parti ipa ts. The primary safety 43 
outcome occurred in 5/36(13.9%) given placebo, and in 8/35(22.9%) and 8/40(20.0%) given 81mg 44 
and 1000mg aspirin respectively (P=0.59). The primary efficacy outcome occurred in 11/38(28.9%) 45 
given placebo, 8/36(22.2%) given aspirin 81mg, and 6/38(15.8%) given 1000mg aspirin (P=0.40). 46 
Planned subgroup analysis showed a significant interaction between aspirin treatment effect and 47 
diagnostic category (Pheterogeneity=0.01) and suggested a potential reduction in new infarcts and deaths 48 
by day 60 in the aspirin treated participants with microbiologically confirmed TBM (11/32(34.4%) 49 
events in placebo vs. 4/27(14.8%) in aspirin 81 mg vs. 3/28 (10.7%) in aspirin 1000mg; P=0.06). CSF 50 
analysis demonstrated aspirin dose-dependent inhibition of thromboxane A2 and upregulation of 51 




The addition of aspirin to dexamethasone may improve outcomes from TBM and warrants 54 
investigation in a large phase 3 trial. 55 
Clinical trial registration: NCT02237365. 56 
Funding 57 









New host-directed therapies are urgently required for all forms of tuberculosis, but especially for 65 
tuberculous meningitis (TBM), the most lethal form of the disease, which kills or disables around half 66 
of sufferers.
1
 Therapeutic strategies to improve outcomes can be broadly divided into those directed 67 
against the bacteria and their enhanced killing, and those directed at the host and the control of the 68 
inflammatory response. To date, attempts to optimise bacteria-directed anti-tuberculosis regimens 69 
have not been shown to clearly benefit patients with TBM.
2,3
 In contrast, host-directed therapy with 70 
adjunctive anti-inflammatory corticosteroids has been shown to reduce mortality from TBM, 71 
although without reduced disability amongst survivors.
4
 There is, therefore, an urgent need to 72 
explore alternative therapeutic strategies that may prevent the long-term neurological sequelae of 73 
TBM and complement the short-term survival benefits of dexamethasone. 74 
Cerebral infarction is the commonest cause of irreversible neurological injury from TBM.
5
 TBM-75 
related infarcts are typically located in the territories of the proximal middle cerebral artery and the 76 
medial lenticulostriate and thalamoperforating vessels, where the basal meningeal inflammatory 77 
exudate is most intense.
5-7
 Their pathogenesis remains controversial, in particular the role of vessel 78 
thrombosis. Some autopsy studies have either failed to find arterial thrombosis associated with 79 
infarcts, or found it to be uncommon;
8
 whereas others have reported that thrombosis is common, 80 
especially when associated with tuberculous vasculitis.
9
 The limited available evidence suggests that 81 




Aspirin acts by irreversibly inhibiting the cyclooxygenase pathway of arachidonic acid metabolism 84 
and the production of prostanoids.
10
 Low dose aspirin (75-150mg) prevents ischaemic 85 
cerebrovascular disease
11
 and higher dose aspirin (up to 4 grams daily) is used for the treatment of 86 
some inflammatory conditions (e.g. rheumatic fever).
12 Its anti-inflammatory effects are thought to 87 
occur at doses >600mg daily, through the inhibition of pro-inflammatory prostaglandins (e.g. PGE2, 88 
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PGF α and PGD2) and the unstable prostanoid, thromboxane A2 (TXA2)
13
. Low dose aspirin causes less 89 
inhibition of pro-inflammatory prostaglandins, but causes clinically significant inhibition of TXA2 and 90 
platelet aggregation. Until recently, the inhibitory effect on platelets and thrombus formation was 91 
thought to e plai  aspiri s ell-documented reduction in the risk of death from stroke and 92 
myocardial infarction.
14
 However, these effects may be augmented by aspiri s ability to trigger the 93 
production of 15-epi-lipoxins, 17R-resolvins and protectins, molecules that alongside the recently 94 
discovered maresins actively promote the resolution of inflammation.
15
 The pro-resolutio  95 
properties of aspirin are not shared with any other non-steroidal anti-inflammatory drugs (NSAID), 96 
or corticosteroids. It represents a potentially unique mode of action by which aspirin, alongside the 97 
prevention of thrombosis, might prevent infarctions and speed resolution of intra-cerebral 98 
inflammation and improve outcomes from TBM. Furthermore, there are intriguing data from murine 99 
models of tuberculosis which suggest aspirin and other non-steroidal anti-inflammatory drugs may 100 
enhance Mycobacterium tuberculosis killing.
16,17
 101 
Two previous trials of adjunctive aspirin for TBM have been reported. The first randomised 118 102 
Indian adults with TBM to standard anti-tuberculosis chemotherapy, with or without aspirin (150mg 103 
daily).
18
 By 3 months, brain magnetic resonance imaging (MRI) proven infarction occurred in 13 104 
(43%) in the placebo arm and 8 (24%) in the aspirin group (P=0.18). Aspirin was associated with a 105 
reduction in mortality (43% versus 22%, P=0.02) without a significant increase in adverse events. The 106 
results are hard to interpret, however, because of the variable use of prednisolone between the 107 
treatment arms. Participants who received prednisolone and aspirin appeared to benefit the most. 108 
The second trial randomised 146 South African children with TBM to standard anti-tuberculosis 109 
chemotherapy plus placebo (n=50), low-dose aspirin (75mg/day) (n=47), or high-dose aspirin 110 
(100mg/kg/day) (n=49).
19
 Aspirin had no significant impact on survival, motor or cognitive outcomes. 111 
We hypothesised that aspirin prevents TBM-related brain infarction by its anti-thrombotic, anti-112 
inflammatory, and pro-resolution effects. We chose to investigate two aspirin doses: a low dose 113 
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(81mg/day) with anti-thrombotic but minimal anti-inflammatory activity; and a higher dose 114 
(1000mg/day) with both anti-thrombotic and anti-inflammatory activity. Our primary objective was 115 
to demonstrate the safety, tolerability, and potential efficacy of 81mg and 1000mg aspirin when 116 
added to dexamethasone for the first 60 days of TBM treatment. Our secondary objective was to 117 
investigate the potential mechanisms of actions of the two aspirin doses by examining the profiles of 118 
lipid mediators, including the pro-inflammatory eicosanoids and aspirin triggered pro-resolving 119 
mediators, in the cerebrospinal fluid (CSF) of participants.  120 




Between October 2014 and May 2016, 192 patients were assessed for eligibility and 120 were 123 
randomised (figure 1 and supplementary file 2): 41 received placebo, 39 received aspirin 81mg/day, 124 
and 40 received aspirin 1000mg/day. Two participants in the placebo group were lost to follow-up 125 
after 57 and 217 days respectively. Gastro-intestinal bleeding event data were missing for 7 126 
participants (3 placebo, 4 aspirin 81mg) because they either died or were lost to follow-up before 127 
day 60. MRI-proven new intracranial bleeding event or infarct data were missing for 15 subjects (6 128 
placebo, 7 Aspirin 81mg , 2 Aspirin 1000mg) because they either died (4 placebo, 6 aspirin 81mg, 1 129 
aspirin 1000mg), were lost to follow-up before day 60 (1 placebo), or they were too unwell to have 130 
scans within 60 ±10 days (2 placebo, 1 aspirin 81mg, 2 aspirin 1000mg). 131 
The per-protocol population excluded 22 participants (figure 1): 2 had a confirmed alternative 132 
diagnosis (Listeria monocytogenes meningitis and Mycobacterium avium intracellulare meningitis), 133 
one had confirmed MDR TBM, and 19 received <30 days of study drug for reasons other than death 134 
(5 placebo; 8 aspirin 81mg; 9 aspirin 1000mg).  135 
Baseline characteristics 136 
Baseline characteristics were balanced between the three treatment groups (table 1). The 137 
predominant gender was male (65.8%), the median age was 41 years and duration of illness was 10 138 
days. Most participants had mild to moderate illness severity, with only 15(12.5%) MRC grade III at 139 
enrollment. Baseline MRI revealed ≥1 infarct in 40/114(35.1%) participants; the placebo and aspirin 140 
1000mg groups had a higher proportion with infarcts (42.5% and 38.5% respectively) than the 141 
aspirin 81mg group (22.9%). According to the published diagnostic criteria 92/120(76.7%) had 142 
definite TBM, 17/120(14.2%) probable, and 9/120(7.5%) possible TBM.
20
 Of the 92 participants with 143 
definite TBM, 42 (45.7%) had M. tuberculosis cultured from the CSF and acid-fast bacilli were seen in 144 
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the CSF in 50 others (54.3%). Amongst patients with culture-confirmed disease, 10/42(23.8%) had 145 
isoniazid resistant infection and one (2.4%) had MDR TBM.  146 
Primary outcomes 147 
The primary safety outcome of gastro-intestinal or cerebral bleeding occurred in 21/111(18.9%): 148 
5/36(13.9%) given placebo, and in 8/35(22.9%) and 8/40(20.0%) given 81mg and 1000mg aspirin 149 
respectively (P=0.59) (table 2). Only one new cerebral bleed occurred (in the aspirin 81mg group): an 150 
asymptomatic micro-haemorrhagic transformation of a lacunar infarct. Four gastro-intestinal 151 
bleeding events were defined as either serious, or grade 3 or 4: two serious haematemesis events in 152 
the placebo group and one in the aspirin 81mg group, and one grade 3 episode of melena in the 153 
aspirin 1000mg. The majority of bleeding events (16/20; 80%) were defined as either grade 1 or 2 154 
events, 15/16 described as >5mls of changed or fresh blood aspirated from a nasogastric tube, and 1 155 
episode of melena (supplementary file 3). None of these events required active management, but 156 
on each occasion the study drug was stopped immediately. 157 
The primary efficacy outcome of new MRI-proven brain infarction or death occurred in 158 
25/112(22.3%): 11/38(28.9%) given placebo, 8/36(22.2%) given aspirin 81mg, and 6/38(15.8%) given 159 
1000mg aspirin. The observed absolute risk reductions in the aspirin 81mg and aspirin 1000mg 160 
groups versus placebo were -6.7% (95% confidence interval (CI) -25.7% to +13.1%) and -13.2% (95% 161 
CI -31.0% to 5.7%), respectively, although the differences were not statistically significant (P=0.40) 162 
(table 2).  163 
The observed risk of a new MRI-proven brain infarction was lower in the aspirin treated patients 164 
compared to placebo, although not statistically significant (P=0.18) (table 2). In addition, 9/15 165 
(60.0%) of brain infarcts seen at baseline in the aspirin 1000mg group resolved by day 60, whereas 166 
resolution only occurred in 1/7 (14.2%) in the aspirin 81mg group and 6/14 (42.9%) in the placebo 167 
group (P= 0.14). There was only one death in the aspirin 1000mg treated participants by day 60. 168 
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In the per-protocol population new infarction or death occurred by day 60 in 19/95(20.0%): 169 
10/34(29.4%) given placebo, 6/31(19.3%) given aspirin 81mg, and 3/30(10.0%) given 1000mg aspirin 170 
(P=0.16) (table 3). The observed absolute risk reductions in the aspirin 81mg and aspirin 1000mg 171 
groups versus placebo were -10.1% (95% CI -29.7% to +11.0%) and -19.4% (95% CI -37.4% to +0.6%), 172 
respectively (P=0.16). No deaths occurred in the aspirin 1000mg group, compared to 13% and 11% in 173 
the aspirin 81mg and placebo groups respectively (P=0.11). 174 
Planned sub-group analyses 175 
Planned sub-group analyses for the primary efficacy outcome are reported in table 4. No clear 176 
subgroup signal was seen for any subgrouping variable except for the diagnostic category which 177 
showed a significant interaction with the aspirin treatment effect (Pheterogeneity=0.01) and suggested a 178 
potential reduction in new infarcts and deaths by day 60 in the aspirin treated participants with 179 
microbiologically confirmed TBM (11/32(34.4%) events in placebo vs. 4/27(14.8%) in aspirin 81 mg 180 
vs. 3/28 1000(10.7%) in aspirin 1000mg; P=0.06). These beneficial effects were most marked in the 181 
aspirin 1000mg group (aspirin 81mg vs placebo: odds ratio (OR) 0.33, 95% CI 0.09-1.20, P=0.093; 182 
aspirin 1000mg vs. placebo: OR 0.23, 95% CI 0.06-0.93, P=0.039) (Figure 2). These effects equate to 183 
the number-needed-to-treat (NNT) to prevent an infarct or death by day 60 of 5 for aspirin 81mg 184 
and 4 for aspirin 1000mg. 185 
Secondary outcomes and adverse events 186 
In the ITT population there was no significant difference in death or disability by day 60 or month 8 187 
across the treatment groups (table 5). The 8-month mortality was 14/118(11.9%): 5/39(12.8%) in 188 
the placebo group versus 6/39(15.4%) and 3/40(7.5%) in the 81mg and 1000mg aspirin groups 189 
respectively (P=0.50; figure 2 panels). Although the observed mortality was lowest in the aspirin 190 
1000mg group at 60 days and 8 months, the proportion of participants in this group with moderate 191 
(6/40(15.0%)) or severe disability (2/40(5.0%)) by 8 months was not significantly different from the 192 
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aspirin 81mg (4/39(10.3%) and 2/39(5.1%)) and placebo  treated participants (7/38(18.4%) and 193 
0/38(0.0%)) (supplementary file 4).  194 
In the per-protocol population, however, there was a trend to better 8-month outcomes in the 195 
aspirin 1000mg group (P=0.13)(table 5). Aspirin at either dose was not associated with a significant 196 
reduction in hospital stay (median 32 days for each group; P=0.84). 197 
MRI brain imaging abnormalities (other than infarcts) were similar between the groups by day 60 198 
and 8 months (supplementary file 5). Hydrocephalus, however, was less common by day 60 in the 199 
aspirin 1000mg group (2/38(5.3%)) than the aspirin 81mg (5/32(15.6%)) and placebo groups 200 
(8/35(22.9%)(P=0.09). None of the participants in the trial with hydrocephalus underwent 201 
ventriculoperitoneal shunting. The proportion of participants in each group with infarcts by month 8 202 
did not differ significantly. 203 
Overall, aspirin was not associated with a significant increase in grade 3 or 4 or serious adverse 204 
events, with the possible exception of more cardiac events in the aspirin groups (P=0.08) (table 6). 205 
The numbers of participants with ≥1 serious adverse event were 12(29.3%) in the placebo arm, 206 
15(38.5%) in the aspirin 81mg arm and 9(22.5%) in the 1000mg arm (P=0.31). Adverse events 207 
resulting in study drug stop or interruption occurred in 7(17.1%) given placebo, 10(25.6%) 81mg 208 
aspirin, and 10(25.0%) 1000mg aspirin (P=0.56). The commonest reason was mild gastro-intestinal 209 
bleeding (20/27; supplementary file 3). Hyponatraemia (plasma sodium <125 mmol/L) was more 210 
common in those treated with placebo (33(80.5%)) than aspirin 81mg (24(61.5%)) or 1000mg 211 
(25(62.5%)) (P=0.11). 212 
CSF lipid mediator profiles 213 
We investigated the impact of aspirin on the concentrations of lipid mediators of inflammation, 214 
extracted, identified and quantified from CSF using lipid mediator profiling and LC-MS/MS (Figure 3 - 215 
child). Partial least squared discriminant analysis 2-dimensional score plot of CSF taken from all 216 
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surviving participants 30 days from randomization showed clustering of lipid mediators according to 217 
treatment group suggesting dose-dependent effects (figure 3A). Furthermore, in those participants 218 
who received >30 days of study drug we compared baseline with day 30 CSF and found dose-219 
dependent inhibition of TXB2 (the stable metabolite of TXA2) and up-regulation of pro-resolving 220 
protectins, with significant differences observed in the aspirin 1000mg group compared to placebo 221 
(figure 3B; supplementary file 6).   222 




There is much current interest in novel host-directed therapies against tuberculosis.
21
 We conducted 225 
a phase 2 randomised controlled trial with the aim of showing the safety and potential efficacy of 226 
either low (81mg/day) or higher (1000mg/day) dose aspirin when added to anti-tuberculosis drugs 227 
and dexamethasone for the treatment of HIV-uninfected adults with TBM. We found that aspirin 228 
was not associated with a significant increase in grade 3 or 4 adverse events. In both the ITT and the 229 
per-protocol population, the observed risk of death or new brain infarction by day 60 was lower in 230 
the aspirin arms compared to placebo, although this was not statistically significant. Planned sub-231 
group analyses, however, suggested that aspirin 1000mg may benefit those with microbiologically 232 
confirmed TBM. This finding was supported by an analysis of CSF lipid mediators of inflammation, 233 
which demonstrated aspirin 1000mg was associated with significant inhibition of pro-thrombotic 234 
TXA2 and upregulation of pro-resolution protectins.    235 
The important characteristics of the trial participants, which influences the generalisability of the 236 
findings, were that they were HIV-uninfected, had relatively mild disease (87.5% MRC grade I or II), a 237 
high proportion (35.1%) had brain infarcts evident at baseline, and most (76.7%) had a 238 
microbiologically confirmed diagnosis of TBM. The high proportion of microbiologically confirmed 239 
disease is especially relevant, as many centres report much lower proportions (typically 20-50%). 240 
The characteristics of populations of suspected but unconfirmed case of TBM may vary substantially 241 
between centres and influence treatment effects. In addition, all participants were treated with 242 
adjunctive dexamethasone, which is known to reduce deaths from TBM in this population.
22
  243 
Combining dexamethasone with aspirin did not significantly increase gastro-intestinal bleeding of 244 
any severity, or any other category of grade 3 or 4 adverse event. There was a non-significant 245 
increase in non-severe (grade 1 or 2) gastro-intestinal bleeding events (mostly small volumes of 246 
digested blood aspirated from nasogastric tubes) in the aspirin-treated participants and in all these 247 
cases the study drug was stopped immediately. A larger trial is needed to determine whether aspirin 248 
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truly increases these events and to assess their clinical significance. However, as the risk of severe 249 
gastric bleeding appears to be very low, the future management of minor bleeding events in aspirin-250 
treated patients could be less conservative, especially as the per-protocol analysis suggested 251 
participants who received >30 days of aspirin may benefit more than those who stopped aspirin 252 
earlier. 253 
Our findings are similar to the previous trial of aspirin (150mg/day) for adults with TBM conducted in 254 
India 
18
, which reported aspirin in combination with prednisolone was associated with a reduction in 255 
brain infarcts (22% versus 55% in controls; P=0.08) and death (13% verus 14% in controls; P=0.05). 256 
Treatment with aspirin without prednisolone was not associated with improved outcomes. In both 257 
the Indian trial and the trial conducted in South African children
19
, which included a high dose 258 
(100mg/kg/day) arm, the use of aspirin was not associated with increased adverse events. In 259 
particular, aspirin did not apprear to increase the risk of gastro-intestinal bleeding in either study. If 260 
these data are taken together with the results of the current study, they strongly suggest aspirin at 261 
doses ranging from 81mg to 1000mg per day can be safely added to anti-tuberculosis and 262 
corticosteroid therapy. Determining which dose is likely to be most effective is difficult, but our 263 
findings suggest that higher doses (1000mg/day or equivalent in children) are likely to more 264 
effective.     265 
The strength of our trial is that it addressed both the potential clinical role of aspirin and its 266 
mechanism of action by serial brain imaging and analysis of a panel of 71 lipid mediators, their 267 
precursors, pathway markers and further metabolites in the CSF. There are, however, some 268 
important limitations. First, assessment of the primary efficacy endpoint required participants to be 269 
well enough to have an MRI at baseline and day 60. Three screened patients were judged too unwell 270 
to have baseline imaging and enter the trial, and 5 participants were too unwell for imaging at day 271 
60. Therefore our findings may not be generalisable to those with very severe disease at baseline.  272 
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The trial was not powered to show an impact on longer term survival or neurodisability and 273 
therefore does not provide definitive, practice-changing evidence that adjunctive aspirin improves 274 
outcomes in all adults with TBM. However, the findings support the hypothesis that aspirin has 275 
effects on tuberculosis-associated neuro-inflammation that are independent of dexamethasone and 276 
may lead to additional improvements in clinical outcomes. The clinical findings need to be 277 
interpreted cautiously, but the planned sub-group analysis suggested a clinical benefit of aspirin in 278 
those with microbiologically confirmed disease, especially at 1000mg. This potential clinical effect is 279 
supported by the CSF analysis, which showed dose-dependent inhibition of TXA2 by aspirin, modest 280 
inhibition of prostaglandins, and the upregulation of potentially protective protectins. The serial 281 
brain images also support the assertion that aspiri s benefit may be driven by the upregulation of 282 
these pro-resolving molecules: 60% of infarcts seen at baseline had resolved by day 60 in the aspirin 283 
1000mg group compared with 14.2% in the aspirin 81mg group and 42.9% in the placebo group.  284 
In summary, this phase 2 randomised placebo controlled trial suggests that daily aspirin 81mg or 285 
1000mg can be given safely with dexamethasone and anti-tuberculosis drugs for the treatment of 286 
HIV-uninfected adults with TBM. The trial also provides new data that indicates aspirin induces dose-287 
dependent inhibition of TXA2 and upregulation of protectins within the central nervous system that 288 
may reduce the incidence and promote the resolution of TBM-associated brain infarcts and 289 
inflammation and thereby improve outcome. These findings provide strong support for the conduct 290 
of a large phase 3 trial of adjunctive aspirin for TBM, but may also have relevance for the treatment 291 
of other forms of tuberculosis, adding to the growing evidence that aspirin and other non-steroidal 292 
anti-inflammatory drugs may be useful novel adjunctive agents in tuberculosis treatment.
23
  293 
  294 
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Materials and Methods 295 
Study design 296 
We conducted a parallel group, double blind, randomised, placebo controlled trial in HIV-uninfected 297 
adults with TBM to assess the safety and efficacy of either 81mg or 1000mg aspirin daily for the first 298 
60 days of treatment with standard anti-tuberculosis drugs and dexamethasone (full study protocol 299 
provided in supplementary file 7). The trial enrolled in-patients at the Hospital for Tropical Diseases, 300 
a 550-bed tertiary referral hospital in Ho Chi Minh City, Vietnam. The trial was approved by the 301 
Oxford Tropical Research Ethics Committee and the Institutional Review Board of the Hospital for 302 
Tropical Diseases and the Ethical Committee of the Ministry of Health, Vietnam. 303 
Participants 304 
Adults ≥ 18 years old) with suspected TBM (at least 5 days of meningitis symptoms, nuchal rigidity, 305 
and CSF abnormalities) and a negative HIV test were eligible to enter the trial. Written informed 306 
consent to participate in the study was obtained from all participants or from their relatives if the 307 
participant could not provide consent due to incapacity. Published diagnostic criteria were used to 308 
categorise participants retrospectively into definite, probable, or possible TBM once the results of all 309 
investigations returned (supplementary file 1).
20
  310 
Patients were excluded if they or their family did not give written informed consent to participate; 311 
they had received >2 days anti-tuberculosis chemotherapy for the current infection; they were 312 
unlikely, for any reason, to be able to have MRI brain imaging within 5 days of randomisation; they 313 
had known or suspected infection with multi-drug resistant (MDR) tuberculosis (resistant to at least 314 
isoniazid and rifampicin); they were unable to take isoniazid, rifampicin, or pyrazinamide at 315 
recommended doses for any reason; they had a history of peptic ulceration or gastro-intestinal 316 
bleeding, or active gastro-intestinal bleeding was suspected; they had taken >1 dose of aspirin (at 317 
any dose) or any other NSAID for any reason within 2 weeks of screening; aspirin was considered 318 
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mandatory for any reason; dexamethasone was contraindicated for any reason; or the patient was 319 
pregnant or breast feeding. 320 
Randomisation and blinding 321 
Randomisation was 1:1:1 to placebo, 81mg aspirin, or 1000mg aspirin according to a computer-322 
generated randomization list using block randomization with variable blocks of length 3 (with 25% 323 
probability) and 6 (with 75% probability) and with stratification by MRC disease severity grade 324 
(defined in table 1). Participant numbers were stratified and assigned sequentially at randomisation, 325 
with each participant receiving a pre-prepared numbered identical package of blinded study drugs. 326 
Treatment allocation was concealed by each treatment pack containing two bottles of study 327 
treatment: one containing 81mg tablets of identical aspirin or placebo, the second containing 328 
identical 500mg tablets of aspirin or placebo. Trial participants and the entire clinical and study team 329 
were blind to the treatment allocation for the duration of the trial. For 60 days, participants took 330 
one 81mg tablet/placebo and two 500mg tablets/placebo (taken every 12 hours), according to their 331 
randomised allocated treatment. Participants unable to swallow were given crushed tablets (which 332 
did not reveal the allocation) via a nasogastric tube at the same doses.  333 
Procedures 334 
Anti-tuberculosis treatment follo ed Viet a s tu er ulosis treat e t guideli es, consisting of oral 335 
isoniazid (5mg/kg/day; maximum 300mg/day), rifampicin (10mg/kg/day), pyrazinamide 336 
(25mg/kg/day; maximum 2g/day) and ethambutol (20mg/kg/day; maximum 1.2g/day) and 337 
intramuscular streptomycin (20mg/kg/day; maximum 1g/day) for 3 months, followed by rifampicin 338 
and isoniazid at the same doses for a further 6 months. All patients received adjunctive 339 
dexamethasone for the first 6 to 8 weeks of treatment as previously described
22
 and oral ranitidine 340 
(300mg at night). For patients infected with M. tuberculosis resistant to isoniazid, the treatment was 341 
adjusted according to local guidelines and the susceptibility of the organism. 342 
17 
 
Lumbar puncture was performed before the start of treatment and on days 30 and 60 as per normal 343 
clinical care. All CSF specimens were stained and cultured by standard methods for pyogenic 344 
bacteria, fungi, and mycobacteria and tested by GeneXpert MTB/RIF assay (Cepheid, USA). Isolates 345 
of Mycobacterium tuberculosis were tested for susceptibility to isoniazid, rifampicin, ethambutol and 346 
streptomycin by mycobacterial growth indicator tube method.
24
  347 
Brain MRI (1.5 tesla; 64 slices) with T1 volume pre and post contrast, T2, FLAIR, gradient echo and 348 
DWI sequences was acquired +/- 5 days from randomisation and then at day 60 (+/- 10 days) and 349 
day 240 (+/- 30 days). All images were separately interpreted by two independent neuroradiologists 350 
(one consultant and one fellow) blind to the treatment allocation, who then determined a consensus 351 
opinion. 352 
Clinical progress and neurological and drug-related adverse events were assessed daily until 353 
discharge from hospital. After discharge, monthly visits were scheduled for clinical evaluation and 354 
laboratory monitoring until 8 months, when a final clinical assessment was made. All participants 355 
were genotyped for leukotriene A4 hydrolase (LTA4H), which has been shown to influence TBM 356 
pathophysiology and outcome, using previously described methods to investigate its influence on 357 
CSF inflammation and aspirin effect.
25
  358 
Outcomes 359 
The primary safety endpoint was the occurrence of clinically significant upper gastro-intestinal 360 
bleeding and any cerebral bleeding confirmed by brain imaging by 60 days from randomisation. 361 
Clinically significant upper gastro-intestinal bleeding was defined as vomiting fresh or changed blood 362 
of any volume; passing melena; an unexplained drop in haemoglobin concentration of >2g/L; or 363 
>5mls of fresh or changed blood aspirated from nasogastric tube. The primary efficacy endpoint was 364 
any new MRI-proven brain infarction or death by 60 days.  365 
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The secondary endpoints were the number of grade 3&4 and serious adverse events by day 60 from 366 
randomisation; mortality over the first 240 days from randomisation; duration of hospital stay; 367 
neurological disability (as assessed by the modified Rankin score) by days 60 and 240; the proportion 368 
of patients with MRI-proven infarction by day 240; and the resolution of CSF inflammation by day 30 369 
through measurement of lipid mediators.  370 
CSF lipid mediator profiling  371 
Lipid mediators were measured by liquid Chromatography-tandem mass spectrometry (LC-MS/MS) 372 
on baseline and day 30 CSF (archived at -80
o
C). Methods have been previously described,
26
 and are 373 
briefly summarised here. 374 
Baseline and day 30 CSF (archived at -80
o
C) was placed in 2 volumes ice-cold methanol containing 375 
deuterium labelled PGE2 (d4-PGE2); d4-LTB4, d5-LXA4 d5-RvD2, d5-LTC4, d5-LTD4, and d5-LTE4 (500pg 376 
each; Cayman Chemicals). These were kept at -20
o
C for 45 minutes to allow for protein precipitation 377 
and lipid mediators were extracted using C-18 based Solid Phase Extraction as previously 378 
described.
26
 Methyl formate fractions were brought to dryness using a TurboVap LP (Biotage) and 379 
products suspended in water-methanol (80:20 vol:vol) for Liquid Chromatography-tandem mass 380 
spectrometry (LC-MS/MS) based profiling. A Shimadzu LC-20AD HPLC and a Shimadzu SIL- 20AC 381 
autoinjector (Shimadzu, Kyoto, Japan), paired with a QTrap 5500 (ABSciex, Warrington, UK) were 382 
utilised and operated as previously described
27
. To monitor each lipid mediator and deuterium 383 
labelled internal standard, a Multiple Reaction Monitoring method was developed using parent ions 384 
and characteristic diagnostic ion fragments.
26
 This was coupled to an Information Dependent 385 
Acquisition and an Enhanced Product Ion scan. Identification criteria included matching retention 386 
time to synthetic standards and at least six diagnostic ions in the MS-MS spectrum for each 387 
molecule. Calibration curves were obtained for each molecule using authentic compound mixtures 388 
and deuterium labelled lipid mediator at 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50, 100, and 200 pg. Linear 389 
calibration curves were obtained for each lipid mediator, which gave r
2
 values of 0.98 – 0.99.  390 
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Statistical analysis 391 
The sample size of 40 per arm was chosen based on clinical and feasibility considerations. Our 392 
objective was to provide estimates of safety and efficacy, alongside potential mechanisms of action, 393 
which would inform the design and execution of a larger phase III trial; we did not expect to show 394 
clinically definitive efficacy in this phase 2 trial. We assumed a risk of new MRI-proven brain 395 
infarction or death within 60 days of approximately 40% in the control arm. Based on the results of 396 
the trial performed by Misra et al,
18
 we assumed that 81 mg aspirin daily may reduce this risk to 20% 397 
and the risk in the 1000 mg aspirin daily arm to between 20-40%. Given these estimates our 3 arm 398 
trial would have approximately 75% power to detect such an effect at the one-sided 10% 399 
sig ifi a e le el i.e. to ge erate ild e ide e  a d appro i atel  % po er to dete t it at the 400 
conventional one-sided 2.5% significance level. 401 
Cerebral bleeding associated with TBM is extremely rare (estimated at <0.01% of all patients), but it 402 
is possible it may be more common in those treated with aspirin. It was therefore included in the 403 
primary assessment of safety. The proportion of HIV-uninfected patients with clinically significant 404 
gastro-intestinal bleeding from our most recent trial of hyper-intensive anti-tuberculosis 405 
chemotherapy in Vietnam was about 1% (3/278).
3
 Assuming this same risk of bleeding in the aspirin 406 
arms, the probability that the upper limit of the 95% confidence interval remains below 12.9% is 407 
more than 92%. If the risk of bleeding is 10% in one of the aspirin arms, the probability that the 408 
lower limit of the 95% confidence interval remains above 2.5% is 78%.  409 
Statistical analysis followed the protocol and a predefined statistical analysis plan. The main 410 
population for all analyses was the intention-to treat population (ITT), which included all randomized 411 
participants, analysed according to the randomized treatment arm. A per-protocol population was 412 
defined by excluding participants with a confirmed alternative diagnosis to TBM; those with 413 
confirmed MDR-TBM; and those who received < 30 days of study drug for reasons other than death.  414 
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The risk of clinically significant upper-gastro-intestinal bleeding and image-proven cerebral bleeding 415 
by 60 days were summarized as numbers and proportion in each group together with two-sided 95% 416 
confidence intervals for risk differences between groups calculated by the Wilson score method. 417 
Comparison between the three arms was based on the chi-square test of independence. The primary 418 
efficacy endpoint of new MRI-proven brain infarction or death by 60 days was analysed in the same 419 
way. For the secondary endpoint, a linear-by –linear trend test (also called Cochran–Armitage test 420 
for trend) was performed to assess the association between disability score and the three arms.
28
 421 
Subgroup analyses for the  primary efficacy endpoint were conducted using logistic regression in 422 
pre-defined subgroups according to TBM grade (I, II, or III); previous tuberculosis treatment; TBM 423 
diagnostic category (definite versus probable/possible); drug resistance (MDR-TB, rifampicin mono-424 
resistance, isoniazid resistance (with or without streptomycin resistance), no or other resistance); 425 
and leukotriene A4 hydrolase (LTA4H) genotype (CC, CT, TT). We fitted a logistic regression model 426 
usi g Firth s orre tio  to the likelihood e ause  there ere su groups ithout e e ts.29 427 
Heterogeneity of the treatment effect across sub-groups was tested via a likelihood ratio test for the 428 
interaction term between treatment and the grouping variable in a logistic regression model. 429 
To assess differences of lipid mediators between the different treatment groups partial least squares 430 
discriminant analysis was conducted using SIMCA 13.0.3 software (Umetrics, San Jose, CA), 
27
 where 431 
mediators displaying a Variable Importance in Projection scores greater than 1 were taken as 432 
displaying significant correlation with the treatment group. This parameter estimates the 433 
importance of a variable in the Partial Least Squares projections with scores greater than 1 indicating 434 
that a specific variable is important in a given model. 435 
No imputation of missing data was performed and the threshold for assuming statistical significance 436 
was P<0.05 for all analyses. For the analysis of gastro-intestinal/cerebral bleeding by day 60, patients 437 
lost to follow-up or dead before day 60 (without prior bleeding) were excluded from the analysis to 438 
avoid under estimating the true proportion of bleeding in the aspirin groups. The analysis of the 439 
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primary efficacy endpoint excluded patients with missing baseline or follow-up MRI scans (except for 440 
prior death). All statistical analyses were performed with the statistical software R v3.1.2.
30
 441 
An independent data and safety monitoring board reviewed the unblinded safety data after 39 and 442 
94 participants were enrolled. The trial was not stopped early. The trial was registered on 443 
clinicaltrials.gov, NCT02237365. 444 
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Table 1 Baseline characteristics 549 






Age (years) – median(IQR) 43 (33-49) 39 (34-48) 40 (31-53) 
Male gender- no.(%) 27 (65.9) 28 (71.8) 24 (60.0) 
Weight (kg) 50 (44-60) 50 (45-60) 50 (47-58) 
Previous tuberculosis treatment- 
no.(%) 
3 (7.3) 1 (2.6) 1 (2.5) 
Illness duration (days) – 
median(IQR) 
10 (9-14) 10 (8-15) 10 (8-14) 
















Glasgow Coma Score (/15) – 
median(IQR) 
15 (14-15) 15 (14-15) 15 (14-15) 
Cranial nerve palsy- no.(%) 12 (29.3) 9 (23.1) 12 (30.0) 
Hemiplegia- no.(%) 3 (7.3) 0 1 (2.5) 
Paraplegia- no.(%) 1 (2.4) 4 (10.3) 1 (2.5) 
Chest radiograph: - no.(%) 
- Normal 
- Miliary tuberculosis 













Plasma sodium (mmol/L) – 
median(IQR) 
127 (124-131) 130 (125-134) 129 (125-132) 
CSF: – median(IQR) 





















































Brain imaging performed: - no.(%) 
- Normal 






















DST available– no. ¶ 
- No isoniazid or rifampicin 
resistance – o. %  ǁ 
- Isoniazid resistant- no.(%) 
- Rifampicin resistant- no.(%) 





















Initial anti-tuberculosis drug 

































IQR= inter-quartile range 550 
†MRC denotes modified British Medical Research Council criteria. Grade I indicates a Glasgow coma score of 551 
15 with no neurologic signs, grade II a score of 11 to 14 (or 15 with focal neurologic signs), and grade 552 
III a score of 10 or less. 553 
§Diagnostic categories were assigned according to the consensus case definition (table S1)
20
. Confirmed other 554 
diagnosis was only made based on microbiological evidence. 555 
¶DST= drug susceptibility test. 556 
ǁ MDR (multidrug-resistance) is defined as resistance to at least both isoniazid and rifampicin. In all categories, 557 
other resistance may be present. 558 
# Rifampicin (R), Isoniazid (H), Pyrazinamide, Ethambutol (E), Streptomycin (S) 559 
  560 
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Primary safety outcomes 
Gastro-intestinal bleeding or 
MRI-proven intracranial 
bleeding event † 
5/36 (13.9%) 8/35 (22.9%) 8/40 (20.0%) Aspirin 81mg vs placebo: 9.0% (-9.3 to 26.9%) 





5/38 (13.2%) 7/35 (20.0 %) 8/40 (20.0 %) Aspirin 81mg vs placebo: 6.8% (-10.5 to 24.4%) 




bleeding event  
0/35 (0%) 1/32 (3.1%) 0/38 (0%) Aspirin 81mg vs placebo: 3.1% (-7.1 to15.7%) 
Aspirin 1000mg vs placebo: 0.0% (-9.9 to 9.2%) 
0.30 
Primary efficacy outcomes 
New MRI-proven brain 
infarction or death 
11/38 
(28.9%) 
8/36 (22.2%) 6/38 (15.8%) Aspirin 81mg vs placebo: -6.7% (-25.7 to 13.1%) 
Aspirin 1000mg vs placebo: -13.2% (-31.0 to 
5.7%) 
0.40 
New MRI-proven brain 
infarction* 
8/35 (22.9%) 2/30 (6.7%) 5/37 (13.5%) Aspirin 81mg vs placebo: -16.2% (-33.1 to 2.0%) 
Aspirin 1000mg vs placebo: -9.3% (-27.2 to 8.7%) 
0.18 
Death  4/41 (9.8%) 6/39 (15.4%) 1/40 (2.5%) Aspirin 81mg vs placebo: 5.6% (-9.5 to 21.1%) 
Aspirin 1000mg vs placebo: -7.3% (-20.2 to 4.7%) 
0.14 
† Gastro-intestinal bleeding event data are missing for 7 participants (3 placebo, 4 aspirin 81mg) because they either died or were lost to follow-up before 562 
day 60. MRI-proven new intracranial bleeding event or infarct data are missing for 15 subjects (6 Placebo, 7 Aspirin 81mg , 2 Aspirin 1000mg) because they 563 
28 
 
either died (4 placebo, 6 aspirin 81mg, 1 aspirin 1000mg), were lost to follow-up before day 60 (1 placebo), or they were too unwell to have scans within 60 564 
±10 days (2 placebo, 1 aspirin 81mg, 2 aspirin 1000mg).  A participant was excluded from the analysis of the combined primary safety endpoint if they had 565 
missing data for both gastro-intestinal bleeding event and MRI-proven intracranial bleeding event, or if information about one event type is missing and the 566 
other event type did not occur (i.e. participants for which it is unclear due to missing data whether the combined event occurred or not are excluded to 567 
avoid under-estimation of the true safety risk). 568 
* 18 participants (6 Placebo, 9 Aspirin 81mg, 3 Aspirin 1000mg) did not have MRI information at either baseline (±7 days) or day 60 (± 10 days). For death 569 
status, the patient lost to follow-up after 57 days was treated as being alive. Patients were excluded from the combined primary efficacy endpoint if they 570 
were alive but MRI information was missing. One patient (Placebo) had both a new MRI-proven brain infarction event and death.  571 
  572 
  573 
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Absolute risk difference [%] (95% confidence 
interval) 
Overall comparison  
P-value 
New MRI-proven brain 
infarction or death† 
10/34 
(29.4%) 
6/31 (19.4%) 3/30 (10.0%) Aspirin 81mg vs placebo: -10.1% (-29.7 to 
11.0%)  
Aspirin 1000mg vs placebo: -19.4% (-37.4 to 
0.6%) 
0.16 
New MRI-proven brain 
infarction 
7/31 (22.6%) 2/27 (7.4%) 3/30 (10.0%) Aspirin 81mg vs placebo: -15.2% (-33.2 to 4.3%) 
Aspirin 1000mg vs placebo: -12.6% (-31.0 to 
6.6%) 
0.22 
Death 4/36 (11.1%) 4/31 (12.9%) 0/31 (0%) Aspirin 81mg vs placebo: 1.8% (-14.4 to 19.1%) 
Aspirin 1000mg vs placebo: -11.1% (-25.3 to 
1.8%) 
0.11 
† 10 participants (5 placebo, 4 aspirin 81mg, 1 aspirin 1000mg) did not have MRI information at either baseline (±7 days) or day 60 (± 10 days). One 575 





Table 4. Sub-group analyses of the primary efficacy outcome in the intention-to-treat population 579 



































































- Rifampicin mono-resistance 
- Isoniazid resistance (with or without 
streptomycin resistance) 


















































 †  participants not genotyped. P-value for the heterogeneity was obtained from likelihood ratio tests for an interaction term between treatment 580 
and the grouping variable in a logistic regression model. 581 
* Outcomes unavailable in 2 participants in the placebo group with DST available (one lost to follow-up at day 57 and one did not have MRI information 582 
at day 60)  583 
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Rankin score categories by 60 
days† 
    
- Complete recovery 6/37(16.2%) 11/39(28.2%) 9/40(22.5%)  
- Intermediate 22/37(59.5%) 16/39(41.0%) 22/40(55.0%) 0.61 
- Death or severely disabled 9/37(24.3%) 12/39(30.8%) 9/40(22.5%)  
Rankin score categories by 8 
months 
    
- Complete recovery 18/39(46.1%) 23/39(59.0%) 22/40(55.0%)  
- Intermediate 10/39(24.6%) 7/39(17.95%) 11/40(27.5%) 0.29 




Rankin score categories at 60 
days 
    
- Complete recovery 6/33(18.2%) 9/31(29.0%) 7/31(22.6%)  
- Intermediate 21/33(63.6%) 15/31(48.4%) 19/31(61.3%) 0.69 
- Death or severely disabled 6/33(18.2%) 7/31(22.6%) 5/31(16.1%)  
Rankin score categories by 8 
months 
    
- Complete recovery 17/35(48.6%) 20/31(64.5%) 19/31(61.3%)  
- Intermediate 9/35(25.7%) 5/31(16.1%) 9/31(29.0%) 0.13 
- Death or severely disabled 9/35(25.7%) 6/31(19.4%) 3/31(9.7%)  
 586 
† Complete recovery = Rankin score 0; Intermediate = Rankin score 1 or 2; Death or severely 587 
disabled = Rankin score 3-6. 3 participants in the placebo group missed their day 60 assessment and 588 
2 were lost to follow-up at day 57 and 217. P-values refer to a linear-by-linear trend test for disability 589 
scores 590 
  591 
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Table 6. Summary of clinical grade 3 or 4 adverse events by randomised group 592 
Event Placebo  
(n=41) 















All events 11 (26.8%) (17) 17 (43.6%) (33) 9 (22.5%) (16) 0.11 
     
Allergic events 
- Rash 
- Stevens Johnsons 
syndrome* 
1 (2.4%) (1) 
1 (2.4%) (1) 
0 
1 (2.6%) (2) 
0 






0 3 (7.7%) (3) 
3 (7.7%) (3) 




1 (2.4%) (1) 
1 (2.4) (1) 
0 
4 (10.3%) (4) 
4 (10.3%) (4) 
0 
3 (7.5%) (3) 
2 (5.0%) (2) 
1 (2.5%) (1) 
0.31 
Gastrointestinal events 
- Vomiting blood 
- Melena 
2 (4.9%) (2) 
2 (4.9%) (2) 
0 
1 (2.6%) (1) 
1 (2.6%) (1) 
0 
1 (2.5%) (1) 
0 




1 (2.4%) (2) 
1 (2.4%) (2) 
1 (2.6%) (1) 





- Cranial nerve palsy 
- Fall in GCS ≥2 points for 
≥2 days 
4 (9.8%) (5) 
0 
1 (2.4%) (1) 
0 
2 (4.9%) (2) 
9 (23.1%) (13) 
1 (2.6%) (1) 
2 (5.1%) (2) 
1 (2.6%) (1) 
5 (12.8%) (5) 
3 (7.5%) (5) 
0 
1 (2.5%) (1) 
0 




- Respiratory failure 
4 (9.8%) (4) 
0 
4 (9.8%) (4) 
8 (20.5%) (9) 
1 (2.6%) (1) 
8 (20.5%) (1) 
4 (10.0%) (4) 
0 
4 (10.0%) (4) 
0.30 
Other events† 2 (4.9%) (2) 0 2 (5.0%) (2) 0.54 
* Event related to rifampicin, not study drug 593 
P- alues refer to Fisher s e a t test for the number of participants with at least one event. 594 
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  605 
192 patients assessed for eligibility 
72 patients excluded† 
30 did not meet inclusion criteria 
10 declined to participate 
33 had diagnosis other than TBM 
120 participants randomised 
41 allocated to placebo 39 allocated to aspirin 
81mg 
40 allocated to aspirin 
1000mg 
41 included in the 
intention-to-treat 
analysis 
39 included in the 
intention-to-treat analysis 
40 included in the 
intention-to-treat 
analysis 
36 included in the per-
protocol analysis 
31 included in the per-
protocol analysis 
31 included in the per-
protocol analysis 
0 withdrew 
2 lost to 
follow-up 
0 withdrew 
0 lost to 
follow-up 
0 withdrew 












1 MDR TB 




9 <30 days of 
study drug 
† Further details of reaso s for e lusio  gi e  i  supplementary file 2 (table S2). One participant 




Figure 2. Forest plots of ITT, per-protocol and planned sub-group analysis of aspirin 81mg versus 606 
placebo (A) and aspirin 1000mg versus placebo (B) for the primary efficacy outcome. Estimates for 607 
subgroups without events were obtained via Firth’s pe alized likelihood. Panels show 8-month 608 






  615 
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C (panel within figure 2). ITT population survival in each group over 8 months 616 
  617 
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Figure 3. LCMS lipid mediator profiles in the CSF of adults with TBM according to treatment with 623 
aspirin or placebo. CSF was collected from participants at baseline and 30 days after 81mg, 1000mg 624 
or placebo administration. (A) Partial least squares discriminant analysis 2-dimensional score plot of 625 
the distinct LM-SPM profiles identified in day 30 CSF at the indicated intervals (top panel) and 626 
corresponding 2-dimensional loading plot. Grey ellipse in the score plots denotes estimated 95% 627 
probability regions (bottom panel). Grey circles in the loading plot represent LM with a variable in 628 
i porta e s ore ≥ . B) Relative regulation of Thromboxane B2 (the stable TXA2 further 629 
metabolite), Prostaglandins (PGD2, PGE2, PGF ) and Protectins (PD1, 17R-PD1, 22-OH-PD1, 10S, 17S-630 
diHDHA, PCTR1, PCTR2 and PCTR3) by day 30 compared to baseline values (absolute values given in 631 
supplementary file 6). Results for B are mean ± s.e.m, n=30 for placebo, n=26 for 81mg and n=26 for 632 
1000mg group. Comparisons between treatment groups assessed using one-way ANOVA followed by 633 







  639 
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Figure 3 – figure supplement 1: Lipid mediator profiles of CSF from participants with TBM. Lipid 640 
mediators (LM) were extracted, identified and quantified using LM profiling . (A,B) Multiple reaction 641 
monitoring chromatograms for identified mediators. (C) tandem mass fragmentation spectra 642 
employed in the identification of PD1 and 15-epi-LXA4. Results are representative of 82 patients.  643 
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